Yaş tip yaşa bağlı makula dejenerasyonunda intravitreal ranibizumab tedavisinin etkinliği
Yükleniyor...
Dosyalar
Tarih
2015
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Trakya Üniversitesi Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Bu çalışmada, yaş tip yaşa bağlı makula dejenerasyonunda intravitreal ranibizumab tedavisinin etkinliğini araştırmayı amaçladık. Hasta dosyaları retrospektif olarak incelendi. Şubat 2012 ve Kasım 2014 yılları arasında Trakya Üniversitesi Tıp Fakültesi Göz Hastalıkları Anabilim Dalı Retina Biriminde intravitreal ranibizumab tedavisi yapılan ve en az 12 aylık takibi tamamlanan 61 hastanın 61 gözü çalışmaya dahil edildi. Hastaların tedavi öncesi klinik muayene ve demografik özellikleri, ranibizumab enjeksiyon sayısı, takip süresi, tedavi öncesi ve kontrollerdeki en iyi düzeltilmiş görme keskinliği, santral fovea kalınlığındaki değişim değerlendirildi. İntravitreal ranibizumab tedavisi standart 3 doz uygulamanın ardından takiplerde görme ve optik koherens tomografi bulgularına göre tekrarlandı. Hastaların 33'ü kadın, 28'i erkekti. Ortalama yaş 73,57±8,01 idi. Gözlerin 25' inde gizli tip lezyon, 36' ünde ise klasik bileşeni bulunan (minimal veya baskın klasik) lezyon mevcuttu. Ortalama ranibizumab enjeksiyonu 3,85 (3-6) olarak bulundu. Hastaların tedavi başlangıcında ortalama görme keskinliği 0,79±0,61 logMAR ünit iken, 12.ayda ortalama görme keskinliği 0,71±0,54 logMAR ünit saptandı. Santral foveal kalınlık tedavi başlangıcında ortalama 369 mikron iken 12. ayda ortalama 324 mikrona düştü. Tedavi başlangıcı ve takip süresi sonunda en iyi düzeltilmiş görme keskinliğinde 9. aya kadar istatistiksel olarak anlamlı iyileşme, santral foveal kalınlıkta ise tüm kontrollerde istatistiksel olarak anlamlı azalma bulundu. (p<0,05) Çalışmamızda yaş tip yaşa bağlı makula dejenerasyonu hastalarında intravitreal ranibizumab enjeksiyonu takip süresince görme keskinliğini artırarak ve santral fovea kalınlığını azaltarak hem anatomik yarar hem de görsel yarar sağlamıştır.
abstract
In this study , it was aimed to evaluate the efficacy of intravitreal ranibizumab injection for wet type age-related macular degeneration. Medical records of the patients were evaluated retrospectively. Sixty-one eyes of 61 patients who were received intravitreal ranibizumab injections and completed at least 12 months of follow-up at the retina service of the Ophtalmology Department of Trakya University Hospital between February 2012 and November 2014 were included. Baseline clinical examination and demographic characteristics, number of ranibizumab injections, follow up period, change in best corrected visual acuity, central foveal thickness were evaluated. Intravitreal ranibizumab injections after a standard 3 dose injection were repeated according to vision and optical coherence tomography findings. Thirty-three patients were female and 28 were male. Mean age was 73,57±8,01 years. Twenty-five of the lesions were occult and 36 were classic (minimally and predominantly classic). The average number of ranibizumab injections was 3,85 (3-6). Mean visual acuity was 0,79±0,61 logMAR unit at the initial examination and 0,71±0,54 logMAR unit at the end of the 12 mounths follow up. The mean central foveal thickness was 369 micron at the initial examination and 324 micron at the end of the 12 months follow up. There were statistically significant improvement up to 9. months visual acuities and while all controls were statistically significant decrease central foveal thickness (p<0,05).
abstract
In this study , it was aimed to evaluate the efficacy of intravitreal ranibizumab injection for wet type age-related macular degeneration. Medical records of the patients were evaluated retrospectively. Sixty-one eyes of 61 patients who were received intravitreal ranibizumab injections and completed at least 12 months of follow-up at the retina service of the Ophtalmology Department of Trakya University Hospital between February 2012 and November 2014 were included. Baseline clinical examination and demographic characteristics, number of ranibizumab injections, follow up period, change in best corrected visual acuity, central foveal thickness were evaluated. Intravitreal ranibizumab injections after a standard 3 dose injection were repeated according to vision and optical coherence tomography findings. Thirty-three patients were female and 28 were male. Mean age was 73,57±8,01 years. Twenty-five of the lesions were occult and 36 were classic (minimally and predominantly classic). The average number of ranibizumab injections was 3,85 (3-6). Mean visual acuity was 0,79±0,61 logMAR unit at the initial examination and 0,71±0,54 logMAR unit at the end of the 12 mounths follow up. The mean central foveal thickness was 369 micron at the initial examination and 324 micron at the end of the 12 months follow up. There were statistically significant improvement up to 9. months visual acuities and while all controls were statistically significant decrease central foveal thickness (p<0,05).
Açıklama
Tıpta Uzmanlık Tezi
Anahtar Kelimeler
Yaş Tip Yaşa Bağlı Makula Dejenerasyonu, Görme Keskinliği, İntravitreal Ranibizumab, Wet Type Age Related Macular Degeneration, Intravitreal Ranibizumab, Visual Acuity
